<DOC>
	<DOCNO>NCT01362413</DOCNO>
	<brief_summary>The aim study determine whether evaluation pro-osteogenic activity autologous serum may predict effectiveness platelet gel regenerate bone tissue patient nonunions long bone . Serum sample collect surgery , pro-osteogenic activity evaluate use bioactivity test ( mineralization assay ) . In order determine whether pro-osteogenic activity serum able discriminate individual achieve achieve bone consolidation , laboratory result correlate clinical radiographic result 12 month , patient consider heal heal .</brief_summary>
	<brief_title>Validation Laboratory Test Predicting Bone Tissue Regeneration</brief_title>
	<detailed_description>Pseudarthrosis ( 'nonunions ' ) define bone movement occur 6 month traumatic event consequence inadequate healing fracture . The use regenerative medicine treat recalcitrant pseudarthrosis consider promising strategy promote bone consolidation . Among various approach use , local cell therapy base autologous mesenchymal stromal cell ( MSC ) , combine without growth factor , extensively use . MSC reside within stromal compartment bone marrow may obtain iliac crest . Growth factor may discharge platelet gel ( PG ) obtain activation autologous platelet concentrate . Nevertheless , result recent clinical study show mention regenerative approach show failure rate approximately 30 % ( Calori et al , 2008 ) . The availability laboratory test may predict regenerative capacity PG may help orthopaedic surgeon address decision regard regenerative approach , e.g . use non use autologous platelet concentrate enhance use autologous derivative recombinant factors.The rationale use platelet concentrate pseudarthrosis significant reduction osteoinductive growth factor observe lesion site ( Gandhi et al. , 2005 ) . Platelet gel mimic happen physiologically bone injury , platelet entrap clot within fibrin matrix . Platelet activation determines release various growth factor promote bone healing . The optimal level ratio growth factor synergistic effect efficient single recombinant molecule , even though data available relevant molecule optimal amount . In context , vitro mineralization assay could valid tool assess pro-osteogenic activity platelet gel , thus obviate measurement myriad platelet-derived substance . The aim study determine whether evaluation pro-osteogenic activity autologous serum may predict effectiveness PG regeneration bone tissue patient nonunions long bone . The rationale base follow issue : - 30 % long bone nonunions treat PG , bone consolidation obtain ( Calori et al , 2008 ) ; - proportion growth factor serum comparable observed platelet gel activation , even concentration lower ; - autologous serum able support 'in vitro ' osteogenic differentiation MSCs formation mineral nodule ( mineralization assay ) ( Granchi et al , 2010 ) ; - correlation 'in vitro ' mineralization regenerative capacity demonstrate various experimental model ( De Bari et al , 2008 ) ; - preliminary data obtain lab show patient affected congenital pseudarthrosis tibia presence osteoinductive growth factor serum essential requirement warrant effectiveness local cell therapy MSC PG ( submit paper ) . In order evaluate ability autologous serum induce mineralization vitro investigator use bioactivity test ( mineralization assay ) . For purpose serum sample patient candidate treatment MSC PG collect day surgery use cultivate normal MSC , whose ability mineralize vitro previously verify standard culture condition . Further analysis conduct order determine whether pro-osteogenic property maintain time , serum sample collect 1 month surgery . In order determine whether pro-osteogenic activity serum able predict discriminate individual achieve achieve bone consolidation , laboratory result correlate clinical radiographic result 12 month , patient consider heal heal .</detailed_description>
	<mesh_term>Pseudarthrosis</mesh_term>
	<mesh_term>Fractures , Ununited</mesh_term>
	<criteria>Eligible patient identify accord follow criterion . Inclusion criterion : patient aseptic nonunion long bones candidate treatment platelet gel MSC addition fixation device bone graft ; patient give write consent participate study . Exclusion criterion : patient bone infection ; patient congenital disorder involve skeletal development ; patient treat corticosteroid immunosuppressive agent ; patient suffer mental psychiatric disorder preclude possibility correctly adhere protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>pseudarthrosis</keyword>
	<keyword>mineralization</keyword>
	<keyword>platelet-rich-plasma</keyword>
	<keyword>serum</keyword>
</DOC>